Get the latest news from ASH 2019

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma

University Hospitals Cleveland Medical Center press statement

Publish date:: August 16, 2018

Key clinical point: A phase 1 trial of CAR T therapy is enrolling adult patients with NHL who have not responded to standard therapies.

Major finding: The trial site has the ability to manufacture the cells on site, saving patients time.

Study details: A phase 1 trial to evaluate safety.

Disclosures: The study will be funded by University Hospitals Seidman Cancer Center.

Read the article.

Citation:

University Hospitals Cleveland Medical Center press statement

This Week's Must Reads

Study IDs factors tied to improved survival in Burkitt lymphoma,

Clinical model helps predict outcomes in r/r DLBCL,

Incidence of R/R DLBCL lower than expected in population-based study,

Fragmentation of sickle cell disease care starts in young adulthood,

Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL,

Must Reads in Aggressive Lymphomas

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,

Chemo-Free Regimen Looks Promising in Poor-Prognosis DLBCL,

Menu Close